CVD 2050: Understanding the Role of GLP-1s and the Future of Cardiovascular Disease Management

CVD 2050: Understanding the Role of GLP-1s and the Future of Cardiovascular Disease Management In the rapidly evolving landscape of cardiovascular disease (CVD) management, there is a growing conversation around the potential impact of glucagon-like peptide-1 receptor agonists (GLP-1s). These medications, initially developed for the treatment of type 2 diabetes, have shown promising results in […]